authors
- Saad, F
- Hotte, Sebastien
- North, SA
- Eigl, BJ
- Chi, KN
- Czaykowski, P
- Polllak, M
- Wood, L
- Winquist, E
A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- May 20, 2008
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal